Advanced searches left 3/3

Carboplatin Phase - Crossref

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Phase II study of nimustine, carboplatin, vincristine, and interferon-β with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group

Ninety-seven patients with a Karnofsky Performance Scale score of 50 or higher were accepted in the study. On Day 1 concomitant with radiotherapy, Nimustine, carboplatin, vincristine, and IFN-u03b2 were given; vincristine and IFN;u03b2 were administered on Days 8 and 15, and IFN0b2 were administered by Nimustine, carboplatin, vincristine, and IFN'u03b2; and IFNu03b2 were administered; and IFNu03b2 were administered u03b2; vincrisine and IFNu73b2; u03b2; vincristine and IFN w2; vincristine and IFNu03b2 were administered by radiotherapy; and IFNu03b2 were administered by IFNu03b2; and IFNu03b2; and IFNu03b2; and IFNu03b2 were administered e; and IFNu03b2 were administered on Days 8 and IFN; and IFNu03b2; and IFN; and IFN; and IFN-u03b2 were On the new Days 8 and 15, the timetable for radiotherapy was restored, and ACNU, carboplatin, vincristine, and IFNu03b2 were all administered, as well as the former Day 1 and IFN00b2 on the new Days 8 and 15. The percentages of patients who suffered Grade 3 poisonation during radiotherapy were 14% with neurocytopenia and 7% with thrombocytopenia. Following radiotherapy, seven percent of all adjuvant chemotherapy cycles were attributed to Grade 3 toxicity, as seen in neurocytopenia or thrombocytopenia.

Source link: https://doi.org/10.3171/jns.2006.105.3.385


Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas

The authors wanted to investigate the response rate and toxicity of carboplatin in patients with progressive low-grade glioma in this research. At a dose of 560 mg/m 2 in Thirty-two patients with progressive LGG were treated with carboplatin at 302 mg/m 2. A total of 12 cycles was administered to patients with stable disease. A partial response was achieved in the nine patients after a median of six cycles, but no reaction was obtained in the two patients after five cycles. According to three patients, three patients after three, five, and five cycles were noted, respectively. Two patients with stable disease died of respiratory difficulties. After five cycles, one patient developed hypersensitivity to carboplatin, while another patient developed hypersensitivity to carboplatin, and no one developed nephrotoxicity. Patients with progressive LGG have been seen in patients with progressive LGG who are given a dose of 560 mg/m 2 every four weeks.

Source link: https://doi.org/10.3171/foc.1998.4.4.6


POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

Background Squamous carcinoma of the anal canal is a human papillomavirus-driven disease with poor prognosis in locally advanced or recurrent settings. retifanlimab exhibited significant clinical growth and an anticipated safety profile in patients with advanced SCAC who were undergoing platinum-based chemotherapy in POD1UM-202, according to a report by POD1UM-202. Based on these promising results, POD1UM-303/InterAct 2, a phase III, double-blind, multiregional study, investigates the addition of retitinob to the care carboplatin-u2013paclitaxel in patients with chronic or metastatic SCAC not previously treated with systemic chemotherapy. Patients of inoperable locally recurrent or metastatic SCAC, measurable disease per RECIST v1. 1, and no prior systemic chemotherapy or PD-1-directed therapy will be enrolled and stratified by PD-L1 expression, region, and severity of disease. Patients with well-controlled human immunodeficiency virus infection are eligible. Every 28 days in SOC, patients will receive up to six induction cycles of carboplatin and paclitaxel.

Source link: https://doi.org/10.3389/fonc.2022.935383


Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors

u2014 To find the maximum tolerated AUC Target, determine the maximum tolerated AUC Target and determine the optimum filtered filtration rate based on a specific area under the concentration-versus-time curve and individual glomerular filtration rate. Procedures u2014 In each cat, plasma clearance of technetium Tc 99m-labeled diethylenetriaminepentaacetic acid was determined to determine GFR. In six cats, plasma platinum levels were measured following the discovery of the maximum tolerated AUC Target and AUC Target. This dose of carboplatin was given to thirteen cats; 13 became neutropenic, but only one developed severe neutropenia, and none had neutropenia-related clinical signs; none had neutropenia-associated clinical signs. The difference between AUC Target and the measured value varied from u22120. 23 to 0. 31 min/u00b7mL, which ranged from u22121 to u22121. U22121 121 mL u00b7mL u22121 121 mL The maximum tolerated AUC Target for a single dose of carboplatin was 2. 75 mins.

Source link: https://doi.org/10.2460/ajvr.70.6.770


Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer

Lessons Learned The lack of safety demonstrated by anti-EGFL7 in this phase II trial in non-small cell lung carcinoma in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of improving VEGF inhibition in unselected populations. Epidermal growth factor-like domain 7 is an extracellular matrix-associated protein that is upregulated during angiogenesis and promotes endothelial cell survival. In combination with bevacizumab plus platinum-based therapy for advanced or recurrent non-small cell lung cancer, this phase II trial determined the safety of the anti-EGFL7 antibody, parsatuzumab, in combination with bevacizumab plus platinum-based therapy for advanced or recurrent nonsquamous non-small cell lung cancer. Patients were randomly assigned to placebo or parsatuzumab in combination with bevacizumab and carboplatin/paclitaxel administered on day 1 of each 21-day cycle. Conclusion For first-line NS-NSCLC, there were no reasons for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy.

Source link: https://doi.org/10.1634/theoncologist.2017-0690


Phase I Study of Weekly Nab-Paclitaxel Plus Carboplatin And Concurrent Thoracic Radiotherapy in Elderly Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer

Abstract: A few scientific trials have been published for elderly patients with locally advanced non-small cell lung cancer. In elderly patients with locally advanced NSCLC, we conducted a phase I study to determine the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy. Patients who were eligible received 6 weeks of weekly carboplatin/nab-paclitaxel and parallel thoracic radiotherapy, total dose of 64 Gy in 32 fractions. Using a dose-escalation analysis, Carboplatin was restricted to an area under the plasma concentration time curve of 2 mg/mL/min, and the suggested dose of nab-paclitaxel was determined. Because two patients had dose-limiting toxicity at 40 mg/m 2, the recommended nab-paclitaxel dose was set at 30 mg/m 2 at 30 mg/m 2. The treatment success rate of the 17 patients who were tested at the recommended dosage was 100%. In elderly patients with locally advanced NSCLC, carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy have good tolerability and demonstrate promising efficacy.

Source link: https://doi.org/10.21203/rs.3.rs-591582/v1


Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Purpose AZD1775 is a WEE1 kinase inhibitor that targets G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. Oral AZD1775 as monotherapy or in combination with chemotherapy in patients with refractory solid tumors was evaluated by this phase I research. Patients and Methods In part 1, patients were divided into two doses of AZD1775 and 14 days of observation. In part 2, patients were given AZD1775 as a single dose or two twice per day doses or two once per day doses or two once per day doses in combination with one of the following chemotherapy agents: gemcitabine, cisplatin, or carboplatin. Results Two hundred two patients were enrolled in the study, including nine patients in part 1A and 158 in part 2B, with nine patients in part 2A and nine in part 2B. Patients in TP53 wild-type patients were 21% compared to 12% in TP53 wild-type patients.

Source link: https://doi.org/10.1200/jco.2016.67.5991

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions